Abstract
In this issue of Blood, Haroche and colleagues report significant therapeutic activity of the BRAF inhibitor, vemurafenib, in 3 patients with rare histiocytic conditions, Erdheim-Chester disease and Langerhans cell histiocytosis.
MeSH terms
-
Erdheim-Chester Disease / drug therapy*
-
Female
-
Histiocytosis, Langerhans-Cell / drug therapy*
-
Humans
-
Indoles / therapeutic use*
-
Male
-
Proto-Oncogene Proteins B-raf / genetics*
-
Sulfonamides / therapeutic use*
-
Vemurafenib
Substances
-
Indoles
-
Sulfonamides
-
Vemurafenib
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf